by Alex Kadhim
Researchers at Memorial Sloan Kettering Cancer Center have found the addition of tocilizumab, an interleukin-6 receptor blocker, to standard GVHD prophylaxis modestly reduces inflammation-related...
by Alex Kadhim
Researchers from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) reported that posttransplant cyclophosphamide (PTCy)-based GVHD prophylaxis significantly improves outcomes for...
by Alex Kadhim
Researchers from a large multicenter collaboration, including the Center for International Blood and Marrow Transplant Research and several leading transplant institutions, have found that donor...
by Alex Kadhim
In a review, published in Current Opinion in Pharmacology, researchers from the University of California, Los Angeles and their collaborators highlight CD3⁺CD4⁻CD8⁻ double-negative T cells (DNTs)...
by Alex Kadhim
Researchers from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) conducted the PHYLOS trial and found that posttransplant cyclophosphamide (PTCy)-based prophylaxis significantly reduces the...
by Alex Kadhim
Researchers from the National Cancer Institute (NCI), USA, have demonstrated that intermediate-dose post-transplantation cyclophosphamide (ID-PTCy) at 25 mg/kg/day administered on days 3 and 4...